Policy | August 11, 2021
NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The drug is indicated for mild and transient episodes of heart block
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
